Heramed Ltd (hmd) Logo

Heramed Ltd (HMD)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

HMD Chart

HMD's Principal Activity is the development and manufacture of foetal heart beat monitors and other pregnancy monitoring solutions designed for both home and professional use.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -10.97%
vs ASX 200 (1yr) -45.83%

Size

Market Capitalisation
ASX Rank 1777 of 2,560
Sector Rank 152 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies ICS / GLH / AJJ
EPS -$0.035
DPS $0.00
NTA per share $0.01

Broker Consensus

HMD is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

HeraMED Limited (HMD) is a technology startup developing a lineup of innovative connected pregnancy monitoring solutions for home use. Harnessing state-of-the-art technology with superior UX/UI, HeraMED creating solutions that are medically accurate, scientifically optimized, safe and affordable.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Website www.hera-med.com
Registry Automic Group
Auditor BDO Audit (WA) Pty Ltd
Date Listed 12 Dec 2018

Upcoming Calendar

Date Event
24/08/2021 Report (Interim)
25/02/2022 Report (Prelim)
28/03/2022 Report (Annual)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Jonathan Hart Company Secretary Mar 2020
Mr Doron Birger Non-Executive Director Oct 2018 Director Bio icon

Mr Doron Birger

Non-Executive Director

Mr Birger is the former Chairman of Given Imaging (NASDAQ/TASE:GIVN), CEO of Elron electronic industries (Nasdaq/TASE: ELRN) and was a board member, during different periods, in a variety of publicly traded companies. During such period, he was involved in investments, merger and acquisitions, exits, public offerings on NASDAQ and TASE and private equity rounds totalling billions of dollars. Mr Birger currently serves as chairman and board member and consultant to a variety of technology companies, mainly in the medical device field, and conducts many voluntary and public activities. He was also Chairman of Medigus LTD and Insuline. He was also director of MCS MEDICAL, HBL Hadasit and Icecure.

Mr Tal Slonim Chief Operating Officer,Executive Director Sep 2018 Director Bio icon

Mr Tal Slonim

Chief Operating Officer,Executive Director

Mr Slonim is a qualified engineer and operations manager with over 22 years of experience. He is the co-founder and part-time CEO of Meytar R&D, one of Israel's top R&D services firm. Mr Slonim brings vast knowledge, hands-on capabilities and profound experience in system design of multi-disciplinary, integrated solutions as well as transition to mass manufacturing and production line erection and validation.

Mr David Groberman Chief Executive Officer,Executive Director Sep 2018 Director Bio icon

Mr David Groberman

Chief Executive Officer,Executive Director

Mr Groberman is a mechanical and bio-medical engineer with over 17 years of experience in developing multi-disciplinary medical technologies across a wide spectrum of the industry. He spent over 8 years as co-founder and Chief Technology Officer at Meytar R&D - one of the leading service provide firms in Israel. During his time with Meytar R&D, he gained, hands-on knowledge and capabilities, leading some of the most challenging projects in the field of multi-disciplinary medical and high-tech devices, ranging from implants to invasive mechanical, electro-mechanical and opto-mechanical instruments, surgical apparatuses and applicators, monitoring, diagnosis and scanning equipment.

Mr David Hinton Non-Executive Director Aug 2018 Director Bio icon

Mr David Hinton

Non-Executive Director

Mr Hinton has an career in the information and technology sectors and is currently Chief Financial Officer and Company Secretary of Empired Limited, an ASX listed IT and software services provider and prior to that Amcom Telecommunications Ltd. Mr Hinton is also a Director of Auspire - The Australia Day Council of Western Australia.

Dr Ronald (Ron) Peter Weinberger Non-Executive Chairman,Non-Executive Director Aug 2018 Director Bio icon

Dr Ronald (Ron) Peter Weinberger

Non-Executive Chairman,Non-Executive Director

Dr Weinberger is an experienced technology and business development executive, with a demonstrated history of building significant value at multiple levels in the medical device industry. During his time at Nanosonics, he co-developed their platform technology, launched their breakthrough product Trophon globally and created North American sales team to work alongside GE Healthcare. He also developed the distribution strategy for Europe having partnered with Toshiba Medical Systems (now Canon Medical Systems) and Miele Professional.

Director Transactions

HMD directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
03/08/20 Ronald (Ron) Weinberger Buy +286,000 $0.094 $26,741 On-market trade
20/07/20 David Hinton Buy +333,333 $0.09 $30,000 Participation in share purchase plan
28/11/19 Tal Slonim Issued 1,249,695 $0.185 $231,194 As advised by the company
28/11/19 David Groberman Issued 1,249,695 $0.185 $231,194 As advised by the company

Director Interests

The current holdings of HMD directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Tal Slonim 31/12/2020 N/A 9,245,418 3,651,252 N/A
David Groberman 31/12/2020 N/A 9,245,418 3,651,252 N/A
Ronald (Ron) Weinberger 31/12/2020 486,000 N/A 100,000 N/A
David Hinton 31/12/2020 N/A 358,333 N/A N/A
Doron Birger 05/10/2018 0 N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Mar 16, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Altshuler Shaham Trusts Ltd (Holley Pharma Co Ltd A/C) 10,857,385 6.17%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) 10,853,467 6.17%
Altshuler Shaham Trusts Ltd (David Groberman A/C) 9,245,418 5.25%
Altshuler Shaham Trusts Ltd (Tal Slonim A/C) 9,245,418 5.25%
Freeman Road Pty Ltd (The Avenue A/C) 6,912,365 3.93%
Citicorp Nominees Pty Limited 5,713,618 3.25%
Etchell Capital Ltd 3,512,500 2.00%
HSBC Custody Nominees (Australia) Limited 3,511,142 2.00%
Altshuler Shaham Trusts Ltd (Michael Nenner A/C) 3,040,774 1.73%
Chris Ntoumenopoulos 3,025,000 1.72%
Mayo Clinic 2,767,691 1.57%
Pula Holdings Pty Ltd (Herath Super Fund A/C) 2,019,000 1.15%
Mrs Amandeep Kaur 1,850,000 1.05%
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 1,591,586 0.90%
Cardup Syndicate Holdings Pty Ltd (The Cardup Syndicate A/C) 1,533,750 0.87%
Dr Matthew Farrugia 1,394,739 0.79%
Mr Barry John Ashwin & Dr Desiree Silva 1,388,833 0.79%
Sobol Capital Pty Ltd (Boc A/C) 1,305,555 0.74%
S & S Browne Assets Pty Ltd (S & S Browne Investment A/C) 1,225,000 0.70%
J P Morgan Nominees Australia Pty Limited 1,090,949 0.62%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 11 149 187 580 246 1,173

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Altor Capital Management Pty Ltd 16/03/2021 10,853,467 6.16
David Groberman 16/03/2021 9,245,418 8.91
Tal Slonim 16/03/2021 9,245,418 8.91
Holley Pharmaceutical Group Co Ltd 16/03/2021 10,857,385 10.47

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
10-02-21 Altor Capital Management Pty Ltd 10,853,467 -- 6.16
15-06-20 Freeman Road Pty Ltd 6,912,365 -- 5.33

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.087 30 June
2019 $0.19 28 June
Page Icon
HMD Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.